Actively Recruiting
Predictive Value of Soluble CD146 in Glioblastoma Patients
Led by Assistance Publique Hopitaux De Marseille · Updated on 2024-02-02
55
Participants Needed
1
Research Sites
148 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Glioblastoma is the most common malignant primary brain tumor with poor prognosis because of its diffusive and infiltrative nature. The FDA approved the use of the anti-VEGF antibody bevacizumab in recurrent GBM. However, resistance to this anti-angiogenic reagent is frequent and fails to enhance patients' overall survival. The investigators previously identified one novel mechanism responsible for bevacizumab-resistance in CD146-positive glioblastoma (Joshkon et al. Acta Neuropathol Commun, 2022). Now, the investigators objective is to prospectively monitor the soluble CD146 value in plasma from patients treated by bevacizumab for recurrent glioblastoma. The investigators will collect plasma at baseline, before the first bevacizumab administration, before the second administration, at the time of first MRI evaluation and at progression. Plasma CD146 value will be analyzed by ELISA. The investigators expect to confirm the correlation between soluble CD146 value in plasma and patient response to bevacizumab.
CONDITIONS
Official Title
Predictive Value of Soluble CD146 in Glioblastoma Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients with recurrent IDHwt glioblastoma
- Relapse after standard first line treatment (radio-chemotherapy)
- Candidate for bevacizumab treatment
- Able to be monitored by MRI
- Karnofsky Performance Status (KPS) score of 60% or higher
- Signed written consent form
You will not qualify if you...
- Pregnancy or breastfeeding
- Life expectancy less than 3 months
- Use of bevacizumab as first line treatment
- Presence of other life-threatening diseases
- Under legal protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Service de Neuro-oncologie
Marseille, France, 13005
Actively Recruiting
Research Team
E
Emeline Tabouret
CONTACT
D
DRSMR AP-HM
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here